The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | The impact of MRD in apheresis product in patients with myeloma undergoing autoSCT
Borja Puertas, MD, University Hospital of Salamanca, Salamanca, Spain, discusses the impact of measurable residual disease (MRD) in apheresis product (aMRD) assessed by multiparametric flow cytometry (MFC) in transplant-eligible patients with multiple myeloma (MM). A study involving over 400 patients undergoing autologous stem cell transplantation (autoSCT) highlighted that MRD positivity in the apheresis product correlates with shorter progression-free survival (PFS) and poorer treatment responses. Dr Puertas suggests that MRD positivity may also help identify patients with functional high-risk disease. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
